Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in KRAS-Mutant NSCLC
NCT01833143Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2013
- Primary completion
- Aug 2019
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2013; status: completed.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01833143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01833143.